Clinical bottom line
Pediatric vestibular neuritis (VN) is an uncommon but important cause of acute vertigo in children, characterized by sudden unilateral vestibular dysfunction without auditory symptoms. Recent evidence highlights evolving diagnostic challenges, including variable vestibular test results, and emerging associations with viral infections such as COVID-19 and adenovirus. Management remains largely supportive with corticosteroids and vestibular rehabilitation, but pediatric-specific data are limited. Clinicians should maintain a high index of suspicion for VN in children presenting with acute vertigo and consider updated diagnostic approaches to avoid misdiagnosis and optimize recovery.
What the evidence shows
Vestibular neuritis in children manifests as acute onset vertigo, nausea, and imbalance, typically without hearing loss, reflecting inflammation of the vestibular nerve (Foster et al., 2014). Although well characterized in adults, pediatric VN is less frequently diagnosed, partly due to challenges in clinical assessment and limited pediatric-focused research (Diagnosis and Management of Pediatric Ear and Vestibular Disorders, 2026).
Recent studies underscore that standard vestibular function tests may yield atypical results in children. For example, Skacik et al. (2025) demonstrated that a negative video head impulse test (vHIT) does not exclude VN, emphasizing the need for comprehensive vestibular evaluation including caloric testing and clinical examination. This is particularly relevant in pediatrics, where cooperation with testing can be limited.
Emerging infectious triggers have been implicated in pediatric VN. Tannous et al. (2022) reported cases of VN following COVID-19 infection in children, suggesting a possible post-viral inflammatory mechanism. Similarly, Millichap and colleagues (2006) linked adenovirus infection to VN in pediatric patients, supporting the hypothesis that viral etiologies predominate in this population.
Therapeutic strategies remain extrapolated from adult data. Corticosteroids are commonly used to reduce vestibular nerve inflammation, though pediatric-specific randomized controlled trials are lacking (Lindemann et al., 2023). Vestibular rehabilitation therapy is advocated to promote central compensation and improve functional outcomes (Foster et al., 2014). Early diagnosis and intervention are critical to minimize prolonged disability.
Caveats and uncertainty
The rarity of pediatric VN and variability in clinical presentation contribute to diagnostic uncertainty. Vestibular testing in children is technically challenging and may produce false negatives, as highlighted by Skacik et al. (2025). The sensitivity and specificity of vestibular assessments in pediatric VN require further validation.
The causal relationship between viral infections such as SARS-CoV-2 and VN remains putative and based on case series rather than controlled studies (Tannous et al., 2022). It is unclear whether these viruses directly cause vestibular nerve inflammation or trigger immune-mediated mechanisms.
Evidence supporting corticosteroid use in children is largely extrapolated from adult studies and expert opinion (Lindemann et al., 2023). Optimal dosing, timing, and duration in the pediatric population are not well established. Similarly, the efficacy and protocols for vestibular rehabilitation in children with VN warrant systematic evaluation.
Long-term outcomes and risk of recurrence in pediatric VN are not well characterized, limiting prognostic counseling. Differential diagnoses such as migraine-associated vertigo, benign paroxysmal vertigo of childhood, and central nervous system pathology must be carefully excluded.
How this may change practice
Awareness of pediatric VN as a distinct clinical entity should prompt clinicians to consider it in children presenting with acute vertigo without hearing loss. Incorporating comprehensive vestibular testing beyond vHIT, including caloric testing and clinical bedside maneuvers, may improve diagnostic accuracy.
Recognition of potential viral triggers, including COVID-19, may influence history taking and guide supportive care. While corticosteroids remain a mainstay, clinicians should weigh benefits against potential side effects in children and advocate for research to define pediatric-specific treatment protocols.
Early initiation of vestibular rehabilitation tailored to pediatric patients may enhance recovery and reduce functional impairment. Multidisciplinary collaboration with audiologists and physical therapists experienced in pediatric vestibular disorders is advisable.
Overall, these advancements underscore the need for heightened clinical vigilance, refined diagnostic algorithms, and pediatric-focused therapeutic trials to optimize outcomes in pediatric vestibular neuritis.